73 reports

Opioid Drugs: Global Markets to 2023 Chapter ## Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report Information Sources Methodology Geographic Breakdown Analyst’s Credentials BCC Custom Research Related BCC Research Reports Chapter ## Summary and High

  • Opioid
  • Therapy
  • World
  • Market Shares
  • Five: Competitive Analysis 87
  • Six: Company Profiles 104

Antares Pharma is one of the leaders of drug delivery using gel technology.

  • Opioid
  • Generex Biotechnology Corporation
  • Nitto Denko Corporation
  • Noven Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • It focus in the areas of addiction medicine and pain management by using drug delivery technologies
  • MARKET ANALYSIS 2014

PecFent uses an Archimedes-developed drug delivery technology platform.

  • Opioid
  • Market Size
  • BioDelivery Sciences International, Inc.
  • ProStrakan Group plc
  • Teva Pharmaceuticals Ltd.

(NIA, Grant ##-UG##-AG-##-##) The overall goal of the HCS Research Collaboratory is to strengthen the national capacity to implement costeffective, large-scale research studies that involve health care delivery organizations.

  • Opioid
  • Therapy
  • United States
  • Lightlake Therapeutics Inc.
  • Opiant Pharmaceuticals, Inc.

Non-opioid pain patches offer efficient transdermal drug delivery option for the treatment of various pain conditions for a prolonged period of time.

  • Opioid
  • Pharmaceutical
  • Therapy
  • World
  • Forecast
  • OPNT002 OPIOID ANTAGONIST NASAL SPRAY - PRODUCT STATUS
  • INTRANASAL NALOXONE SPRAY - PRODUCT STATUS

CONSORT MEDICAL PLC, A LEADING ONE-STOP DEVELOPER AND MANUFACTURER OF DRUGS AND PREMIUM DRUG DELIVERY DEVICES, ANNOUNCES ITS INTERIM RESULTS FOR THE SIX MONTHS ENDED ## OCTOBER 2017.

  • Anesthetics
  • Clinical Trial
  • Opioid
  • Pharmaceutical
  • Opiant Pharmaceuticals, Inc.

A Product and Pipeline Analysis of the Opioid Therapeutics and Drug Delivery Market : Increasing Regulation Push for Tamper-resistant Drugs Driving New Generation of Opioids Methodology and Scope ## Executive Summary ## Introduction ## US Opioid Therapeutics Market Overview

  • Opioid
  • Therapy
  • United States
  • Demand
  • Market Size

Intrathecal drug delivery system j.

  • Analgesic
  • Opioid
  • Therapy
  • United States
  • 6.5 OCT 16, 2018: MEDTRONIC LAUNCHES THE CONTROL WORKFLOW TO HELP ELIMINATE ORAL OPIOIDS AND PROVIDE EFFECTIVE PAIN RELIEF
  • 6.3 JAN 18, 2019: MEDTRONIC BEGINS ENROLMENT IN PAIN PUMP TRIAL

" We are striving to simplify targeted drug delivery therapy to make it more accessible.

  • Clinical Trial
  • Injectable Delivery
  • Opioid
  • Pharmaceutical
  • Therapy

Relmada announced positive results from an open-label Phase ## study.

  • Opioid
  • United States
  • Egalet Corporation
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • EXALGO
  • BIODELIVERY SCIENCES INTERNATIONAL, INC, RALEIGH, NC COMPANY OVERVIEW

FENTORA INCORPORATES CIMA LABS' ORAVESCENT ORAL DRUG DELIVERY TECHNOLOGY.

  • Opioid
  • Actavis plc
  • Bedrocan Canada Inc.
  • Insys Therapeutics, Inc.
  • Medical Marijuana, Inc.
  • MUCOADHESIVE FENTANYL DRUG DELIVERY SYSTEM
  • MUCOADHESIVE FENTANYL DRUG DELIVERY SYSTEM - PRODUCT DESCRIPTION

MUCOADHESIVE FENTANYL DRUG DELIVERY SYSTEM MUCOADHESIVE FENTANYL DRUG DELIVERY SYSTEM PRODUCT OVERVIEW MUCOADHESIVE FENTANYL DRUG DELIVERY SYSTEM - PRODUCT STATUS Function Product Description Source: Primary / Secondary Research, GlobalData

  • Opioid
  • Therapy
  • United States
  • Product Initiative
  • PetVivo Holdings, Inc.
  • ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) - PIPELINE BY CINGULATE THERAPEUTICS LLC, H1 2019
  • ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) - PIPELINE BY DURECT CORP, H1 2019

The drug candidate is developed based on transepithelial delivery system (TDS).

  • Neurological Disorder
  • Opioid
  • United States
  • Product Initiative
  • KemPharm, Inc.
  • DRUG OVERDOSE - PIPELINE BY FAB'ENTECH SA, H2 2019
  • R&D Progress

The company also provides transdermal drug delivery systems that enable drug delivery as a form of transdermal patch.

  • Opioid
  • Pharmaceutical
  • United States
  • Company Operations
  • Product Initiative

Assertio also licenses Acuform, its proprietary gastroretentive drug delivery technology.

  • Opioid
  • Pharmaceutical
  • United States
  • Company
  • Collegium Pharmaceutical, Inc.
  • OREXO RAISES USD76 MILLION IN PUBLIC OFFERING OF BOND
  • EQUITY OFFERING

The company employs its proprietary drug delivery technologies in the development of these products.

  • Opioid
  • Pharmaceutical
  • United States
  • Company Financials
  • Orexo US Inc.
  • Deal Type

DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering.

  • Opioid
  • Pharmaceutical
  • United States
  • Company
  • Collegium Pharmaceutical, Inc.
  • Other Significant Developments

The company develops its controlled-release and targeted-release oral solid dosage drugs based on its proprietary technology, Hypermatrix, a multidimensional controlled-release drug delivery platform.

  • Opioid
  • Canada
  • United States
  • Corporate Finance
  • Intellipharmaceutics International Inc.
  • TESA LABTEC GMBH, APR
  • and Table 11.45 outline the base scenario of the fentanyl oral thin film sales

ORAL TRANSMUCOSAL DRUG DELIVERY SYSTEMS HAVE RECENTLY GAINED A LOT OF ATTENTION; ONE OF THE KEY DRIVING FACTORS IS THE PREFERENCE FOR NON- INVASIVE ROUTES OF DRUG DELIVERY.

  • Opioid
  • North America
  • United States
  • Demand
  • Market Size

Deal Rationale Pacira Pharmaceuticals Inc (Pacira) discovers, develops, manufactures and commercializes drugs based on its proprietary DepoFoam drug delivery technology.

  • Opioid
  • Pharmaceutical
  • United States
  • Company Financials
  • Pacira Pharmaceuticals, Inc.
  • Camurus Expands Licensing Agreement with Braeburn Pharma

It develops its drugs based on proprietary and patented drug delivery technologies such as multicaps and locktab.

  • Opioid
  • Pharmaceutical
  • Therapy
  • United States
  • Camurus
  • INDIVIOR PLC
  • TM-002 - DRUG PROFILE

The company develops drugs using ProNeura, a proprietary drug delivery platform, for the treatment of chronic diseases.

  • Opioid
  • Therapy
  • United States
  • Company
  • Product Initiative

Consort Medical CEO Jonathan Glenn said: " We are delighted to announce this agreement with Opiant which highlights our expertise in the nasal delivery of drugs and the value of our unique offering of providing both drug manufacturing and delivery capabilities

  • Opioid
  • United States
  • Company
  • Company Operations
  • Opiant Pharmaceuticals, Inc.
  • Deal Type

(BDSI), a pharmaceutical and drug delivery technology company, completed the private placement of shares of its common stock, for gross proceeds of US$##m.

  • Opioid
  • Pharmaceutical
  • United States
  • Company Financials
  • BioDelivery Sciences International, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

DYSPNEA THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2019* PROMINENT DRUGS DYSPNEA THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2019* DYSPNEA THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TR

  • Clinical Trial
  • Opioid
  • Therapy
  • World
  • Product Initiative

GlobalData Deal Value (US$ million) ##. ## NA NA NA NA Egalet Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 Egalet Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 Egalet Corp' s medical equipment deals activity has been focusing on drug delivery devices

  • Opioid
  • United States
  • Company
  • Company Operations
  • Egalet Corporation

The company discovers, develops and markets transdermal drug delivery products.

  • Opioid
  • United States
  • Company
  • Corporate Finance
  • Egalet Corporation
  • HOVERINK BIOTECHNOLOGIES INC
  • CHEMOTHERAPY INDUCED NAUSEA AND VOMITING - PIPELINE BY SUDA PHARMACEUTICALS LTD, H2 2018

In April 2009, IntelGenx Corp announced positive results for the Phase ## clinical trial of relivar, the first buccal dronabinol drug delivery product, which was developed using IntelGenx' proprietary AdVersa buccal delivery technology.

  • Chemotherapy
  • Opioid
  • United States
  • Product Initiative
  • Helsinn Group
  • SER-227 - DRUG PROFILE
  • R&D Progress

IT IS BASED ON POZ DRUG DELIVERY PLATFORM.

  • Opioid
  • United States
  • Company
  • Product Initiative
  • AcelRx Pharmaceuticals, Inc.
  • Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details

The company offers Intravail, a drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide, and nonpeptide drugs.

  • Opioid
  • Pharmaceutical
  • United States
  • Company
  • Opiant Pharmaceuticals, Inc.